Original articleAssociation with pregnancy increases the risk of local recurrence but does not impact overall survival in breast cancer: A case–control study of 87 cases
Introduction
Pregnancy-associated cancers are typically defined in the literature as cancers occurring during pregnancy or within the year following delivery [1]. They are not uncommon; they occur in 1/10,000 to 1/3000 pregnancies [1], [2], [3], [4]. The cancer that is most frequently associated with pregnancy is breast cancer (BC), with pregnancy-associated BC (PABC) constituting approximately 7% of all BCs in women less than 45 years of age [1], [5]. The incidence of PABC has increased in recent decades in western countries and is expected to continue to grow as women delay childbearing in these countries [1], [6]. The prognosis of PABC remains controversial. Some large retrospective studies have reported that PABC was associated with an increased risk of specific death or recurrence regardless of the patient's age, the tumor size or the pathological characteristics [2], [7], [8], [9], [10], [11], [12], [13], [14], [15]. PABC patients were previously described to have pejorative prognostic factors, such as young age, more locally advanced tumors, and more frequent negative hormone receptor status [14], [16], [17], [18]. After adjustment for age and tumor characteristics, some authors did not find a worse prognosis for PABC patients compared to control BC patients [3], [4], [16], [19], [20]. Furthermore, PABC patients were frequently not offered the recommended treatment strategy, thus resulting in a bias in the interpretation of survival data. We evaluated the prognosis of PABC compared with that of control BC. We examined the factors of therapeutic management and adjusted the data for the currently used prognostic factors (age, tumor stage, hormonal receptor status, human epidermal growth factor receptor 2 [HER2] expression level and proliferation measured as the Ki67 rate). Therefore, we conducted a retrospective case–control study to determine the impact of the pregnancy associated status in our BC population. We matched cases and controls for age and year of diagnosis excluding other known prognosis factors (such as tumor size, node involvement, hormonal or HER2 status) as we expected that these differences could be take into account in the overall assessment of the prognosis of this young population of BC patients.
Section snippets
Patient selection
From the prospective database of all BC patients treated at Centre René Huguenin-Institut Curie (Saint-Cloud, France), we retrospectively selected female patients having first unilateral BC without distant metastasis at the time of the diagnosis who were treated between 1st July 1992 and 30th September 2009. PABC was defined according to the literature as BC diagnosed during pregnancy or in the year following delivery. The medical reports of patients suspected of having PABC based on the
Population characteristics and treatments
Two-hundred sixty-one patients were enrolled in the study, including 87 cases and 174 matched controls. The median follow-up period was 113 months (range 1.8–255.3). No significant differences were observed for the duration of follow-up between the 2 groups (PABC group: median follow-up 111 months, control group: 113 months, p = 0.85). The pathological characteristics of the patients' tumors are summarized in Table 1. The main histological type in both groups was invasive ductal carcinoma.
Discussion
PABC constitutes 7% of BCs in young women, and its incidence is expected to increase [1], [6]. Its prognosis and the underlying therapeutic strategy for affected patients are currently subjects of debate. In this case–control study, we found that PABC patients have worse prognostic factors than controls matched for age at diagnosis, as T3–T4 tumors were more than twice as frequent in PABC patients than controls, and nearly half of the PABC tumors were hormone-negative vs. one third of the
Conclusion
Association of BC with pregnancy is strongly associated with an increased risk of local recurrence, and pregnancy association negates the prognostic value of tumor size. Indeed, small tumors in PABC patients have the same poor prognosis as more advanced tumors in control patients, although no significant difference in prognosis was observed between the PABC and control patients with T3–T4 tumors. In PABC patients, when possible, radical surgery as the first-line treatment rather than
Conflict of interest
The authors declare that they have no conflict of interest and no funding source for this study.
References (25)
- et al.
Worse survival in breast cancer among women with recent childbirth: results from a Swedish population-based register study
Clin Breast Cancer
(Oct 2003) - et al.
Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies
Cancer Treat Rev
(Nov 2012) - et al.
A single-institution study of 117 pregnancy-associated breast cancers (PABC): presentation, imaging, clinicopathological data and outcome
Diagn Interv Imaging
(avr 2014) - et al.
Increasing incidence of pregnancy-associated breast cancer in Sweden
Obstet Gynecol
(Sep 2009) - et al.
Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study
J Clin Oncol Off J Am Soc Clin Oncol
(1 Jan 2009) - et al.
Overall survival from breast cancer in women pregnant or lactating at or after diagnosis. Auckland Breast Cancer Study Group
Int J Cancer J Int Cancer
(17 Sep 1996) - et al.
The impact of pregnancy on breast cancer outcomes in women<or=35 years
Cancer
(15 Mar 2009) - et al.
Increased mortality in women with breast cancer detected during pregnancy and different periods postpartum
Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol
(Sep 2011) - et al.
Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: a population-based linkage study
BJOG Int J Obstet Gynaecol
(déc 2012) - et al.
Effect of pregnancy on prognosis for young women with breast cancer
Lancet
(25 Jun 1994)
Prognosis for patients diagnosed with pregnancy-associated breast cancer: a paired case–control study
São Paulo Med J Rev Paul Med
Evidence of poorer survival in pregnancy-associated breast cancer
Obstet Gynecol
Cited by (20)
Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy
2018, BreastCitation Excerpt :PABC's pathogenic pathway is probably different from that of non-PABC [2,5–7]. It is usually associated with pejorative prognostic factors such as young age, locally advanced tumors, or hormone receptor-negative tumors [4,8,9]. However, so far, studies on PABC have scarcely distinguished breast cancers diagnosed during pregnancy (PREG-PABC) from those diagnosed during the first post-partum year (post-partum PABC; designed as PP-PABC).
Propensity score to evaluate prognosis in pregnancy-associated breast cancer: Analysis from a French cancer network
2018, BreastCitation Excerpt :Furthermore, the maternal prognosis of pregnancy associated breast cancer, and especially the impact of pregnancy, is highly debated. Some authors report that pregnancy itself negatively influences the prognosis by specific involvement of the pro-inflammatory micro-environment of mammary gland, while others suggest that the prognosis is similar in pregnant and non-pregnant patients [5,7,8]. So far, few studies have compared breast cancer in young patients with and without pregnancy [5,9].
Survival probabilities and prognostic factors of pregnancy-associated breast cancer in Malaysian women
2024, Obstetrics and Gynecology SciencePregnancy-associated breast cancer: a multicenter study comparing clinicopathological factors, diagnosis and treatment outcomes with non-pregnant patients
2023, Breast Cancer Research and Treatment